top of page
Pipeline
PIPELINE
TIMELINE
Pipeline
Targets
Indication
HER2
CTN001
HER2-Low Breast Cancer
CD33
CTN008
AML
EGFR/c-Met
CTN005
NSCLC
GPC3
CTN002
HCC
FGFR3
CTN012
Bladder cancer
MUC16
CTN013
Ovarian cancer
EGFR/EGFRvIlI
CTN014
Glioblastoma
OX40
CTN010
Severe atopic dermatitis
2023
2024
CMC & IND Enabling Studies
Lead Discovery/Optimization
Preclinical Studies
Lead Discovery/Optimization
Preclinical Studies
Lead Discovery/Optimization
Preclinical Studies
Lead Discovery/Optimization
Preclinical Studies
Lead Discovery/Optimization
Preclinical Studies
Lead Discovery/Optimization
Preclinical Studies
Lead Discovery/Optimization
Preclinical Studies
bottom of page